Foghorn therapeutics announces first patient dosed in phase 1 combination study of fhd-286 for relapsed and/or refractory aml

Cambridge, mass., aug. 31, 2023 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression, today announced the first patient has been dosed in the phase 1 study of fhd-286 in combination with decitabine or cytarabine in relapsed and/or refractory acute myelogenous leukemia (aml).
FHTX Ratings Summary
FHTX Quant Ranking